{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:57:30Z","timestamp":1791226650775,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.tcm.2005.07.002","type":"journal-article","created":{"date-parts":[[2005,9,22]],"date-time":"2005-09-22T11:21:28Z","timestamp":1127388088000},"page":"202-206","source":"Crossref","is-referenced-by-count":104,"title":["Toward Immunomodulatory and Anti-Inflammatory Properties of Statins"],"prefix":"10.1016","volume":"15","author":[{"given":"Claire","family":"Arnaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Braunersreuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2005.07.002_bib4","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","article-title":"Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis","volume":"35","author":"Amarenco","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.tcm.2005.07.002_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.tcm.2005.07.002_bib6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0008-6363(97)00229-0","article-title":"Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions","volume":"37","author":"Bobryshev","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2005.07.002_bib7","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood.V84.7.2068.2068","article-title":"Leukocyte-endothelial adhesion molecules","volume":"84","author":"Carlos","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.tcm.2005.07.002_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/emm.2002.63","article-title":"Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells","volume":"34","author":"Chung","year":"2002","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.tcm.2005.07.002_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/341619a0","article-title":"T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1","volume":"341","author":"Dustin","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.tcm.2005.07.002_bib12","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.95.15.8880","article-title":"Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase","volume":"95","author":"Endres","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.tcm.2005.07.002_bib13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.RES.83.7.683","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins","volume":"83","author":"Essig","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2005.07.002_bib14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.14.1.591","article-title":"Immune regulation by CD40 and its ligand GP39","volume":"14","author":"Foy","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.tcm.2005.07.002_bib15","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.4049\/jimmunol.174.4.2327","article-title":"Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction","volume":"174","author":"Gegg","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.tcm.2005.07.002_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the actin cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.tcm.2005.07.002_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/01.RES.87.7.616","article-title":"Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells","volume":"87","author":"Hernandez-Perera","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2005.07.002_bib18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/82219","article-title":"Statins as a newly recognized type of immunomodulator","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib20","first-page":"41","article-title":"The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells","volume":"131","author":"Kwak","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.tcm.2005.07.002_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/15271","article-title":"Requirement for CD154 in the progression of atherosclerosis","volume":"5","author":"Lutgens","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40 signalling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.tcm.2005.07.002_bib23","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1161\/01.RES.85.8.e17","article-title":"Protective role of interleukin-10 in atherosclerosis","volume":"85","author":"Mallat","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2005.07.002_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2005.07.002_bib25","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0008-6363(03)00515-7","article-title":"Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells","volume":"59","author":"Mulhaupt","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2005.07.002_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1161\/01.RES.0000018941.10726.FA","article-title":"Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes","volume":"90","author":"Pinderski","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2005.07.002_bib29","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(95)92836-7","article-title":"Cholesterol, diastolic blood pressure, and stroke. 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration","volume":"346","author":"Qizilbash","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","article-title":"Inhibition of proinflammatory cytokine production by pravastatin","volume":"353","author":"Rosenson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/00007890-200105150-00014","article-title":"Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors","volume":"71","author":"Sadeghi","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.tcm.2005.07.002_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyad","volume":"58","author":"Schonbeck","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.tcm.2005.07.002_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1357-2725(00)00016-9","article-title":"CD154 (CD40 ligand)","volume":"32","author":"Schonbeck","year":"2000","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.tcm.2005.07.002_bib36","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/01.CIR.0000043029.52803.7B","article-title":"Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells","volume":"106","author":"Schonbeck","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2005.07.002_bib37","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.tcm.2005.07.002_bib38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo\u2013Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurheartj\/16.1.5","article-title":"Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety","volume":"16","author":"Shepherd","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2005.07.002_bib40","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1161\/01.CIR.0000127616.70152.5D","article-title":"Early intervention with atorvastatin modulates TH1\/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench","volume":"109","author":"Shimada","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2005.07.002_bib41","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI13350","article-title":"Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy","volume":"108","author":"Takemoto","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2005.07.002_bib3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","author":"Tonkin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib42","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1172\/JCI118650","article-title":"Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis","volume":"97","author":"Uyemura","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2005.07.002_bib43","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1101\/gad.11.18.2295","article-title":"Rho GTPases and signaling networks","volume":"11","author":"Van Aelst","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/j.tcm.2005.07.002_bib44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than just lower cholesterol","volume":"348","author":"Vaughan","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(99)00525-2","article-title":"The evolving role of statins in the management of atherosclerosis","volume":"35","author":"Vaughan","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2005.07.002_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00001573-200107000-00001","article-title":"Statin therapy and stroke prevention","volume":"16","author":"Vaughan","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.tcm.2005.07.002_bib47","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","article-title":"Oral simvastatin treatment in relapsing-remitting multiple sclerosis","volume":"363","author":"Vollmer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2005.07.002_bib48","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/01.ATV.0000037098.20829.31","article-title":"3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells","volume":"22","author":"Wagner","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.tcm.2005.07.002_bib49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/mol.59.3.646","article-title":"Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase","volume":"59","author":"Wassmann","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.tcm.2005.07.002_bib50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.tcm.2005.07.002_bib51","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial","volume":"96","author":"Wenke","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2005.07.002_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-year prospective experience","volume":"107","author":"Wenke","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2005.07.002_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2003.10.002","article-title":"HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis","volume":"172","author":"Yilmaz","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2005.07.002_bib54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173805001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173805001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T20:54:49Z","timestamp":1586465689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173805001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S1050173805001210"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2005.07.002","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}